Utilization and tolerance of beta-blockers among patients with AL amyloidosis.
Jean-Jacques VON HUNOLSTEIN : Cardiologue Hopital Civil STRASBOURG Utilization and tolerance of beta-blockers among patients with AL amyloidosis. https://pubmed.ncbi.nlm.nih.gov/34549676/ PMID : 34549676
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatmen
Antoine JOBBE-DUVAL : Cardiologue HCL LYON Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment. https://pubmed.ncbi.nlm.nih.gov/34768388/ PMID : 34768388
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Patricia RÉANT : Cardiologue – CHU de BORDEAUX Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. https://pubmed.ncbi.nlm.nih.gov/34923848/ PMID : 34923848
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.
Emmanuelle BERTHELOT : adjointe chef de service, Cardiologue – APHP CHU Bicêtre Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/32729170/ PMID : 32729170
Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis
Jean-Pierre GUEFFET : Cardiologue Hôpital Privé du Confluent – Nantes https://pubmed.ncbi.nlm.nih.gov/34734/
Mode of death and outcomes of implantable cardioverter defibrillators in transthyretin amyloid cardiomyopathy
Frédéric MOUQUET : Cardiologue CHU de Lille https://pubmed.ncbi.nlm.nih.gov/34843821/
The role of serial (99m)Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis
Pierre TROISFONTAINES – Cardiologue CHR de la Citadelle Liège – BELGIQUE The role of serial (99m)Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis. https://pubmed.ncbi.nlm.nih.gov/34704883/ PMID : 34704883
Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
Erwan DONAL : cardiologue CHU de Rennes Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. https://pubmed.ncbi.nlm.nih.gov/34509404/ PMID : 34509404
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation.
Thibaut WAJCHERT – Dr Junior au CHU de Versailles Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. https://pubmed.ncbi.nlm.nih.gov/32981389/ PMID : 32981389
Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis
Damien EYHARTS – cardiologue CHU de Toulouse Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis https://pubmed.ncbi.nlm.nih.gov/34643339/ PMID : 34643339